Literature DB >> 23601025

Reactivation of hepatitis B virus in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab.

Nobuaki Nakano1, Shigeru Kusumoto, Yasuhito Tanaka, Takashi Ishida, Shogo Takeuchi, Yoshifusa Takatsuka, Shiro Akinaga, Masashi Mizokami, Ryuzo Ueda, Atae Utsunomiya.   

Abstract

The introduction of molecularly targeted drugs has increased the risk of reactivation of hepatitis B virus (HBV), which is a potentially fatal complication following anticancer chemotherapy even in patients who have previously resolved their HBV infection. CC chemokine receptor 4 (CCR4) has been identified as a novel molecular target in antibody therapy for patients with adult T-cell leukemia-lymphoma (ATL) and peripheral T-cell lymphoma, and the humanized anti-CCR4 monoclonal antibody mogamulizumab has been developed. We reported HBV reactivation of an ATL patient with previously resolved HBV infection after mogamulizumab treatment in a dose-finding study for this antibody. Our retrospective analysis using preserved samples also revealed the detailed kinetics of HBV DNA levels before and just after HBV reactivation.
© 2013 The Japan Society of Hepatology.

Entities:  

Keywords:  CC chemokine receptor 4; hepatitis B virus; mogamulizumab; reactivation

Year:  2013        PMID： 23601025     DOI： 10.1111/hepr.12117

Source DB:  PubMed          Journal:  Hepatol Res        ISSN： 1386-6346            Impact factor:   4.288


  14 in total

Review 1.  Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions.

Authors:  Rohit Loomba; T Jake Liang
Journal:  Gastroenterology       Date:  2017-02-20       Impact factor: 22.682

2.  Colitis mimicking graft-versus-host disease during treatment with the anti-CCR4 monoclonal antibody, mogamulizumab.

Authors:  Kenji Ishitsuka; Mutsunori Murahashi; Hiroo Katsuya; Ai Mogi; Michio Masaki; Chisato Kawai; Toshitaka Goto; Masanao Ishizu; Yosuke Ikari; Yasushi Takamatsu; Hideki Ishibashi; Satoshi Nimura; Morishige Takeshita; Kazuo Tamura
Journal:  Int J Hematol       Date:  2015-05-21       Impact factor: 2.490

Review 3.  Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.

Authors:  Man Fai Law; Rita Ho; Carmen K M Cheung; Lydia H P Tam; Karen Ma; Kent C Y So; Bonaventure Ip; Jacqueline So; Jennifer Lai; Joyce Ng; Tommy H C Tam
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.742

4.  Mogamulizumab for adult T-cell leukemia-lymphoma: a multicenter prospective observational study.

Authors:  Kentaro Yonekura; Shigeru Kusumoto; Ilseung Choi; Nobuaki Nakano; Asahi Ito; Youko Suehiro; Yoshitaka Imaizumi; Makoto Yoshimitsu; Kisato Nosaka; Eiichi Ohtsuka; Michihiro Hidaka; Tatsuro Jo; Hidenori Sasaki; Yukiyoshi Moriuchi; Masao Ogata; Hiro Tatetsu; Kenji Ishitsuka; Yasushi Miyazaki; Ryuzo Ueda; Atae Utsunomiya; Takashi Ishida
Journal:  Blood Adv       Date:  2020-10-27

5.  Reactivation of hepatitis B virus (HBV) infection in adult T-cell leukemia-lymphoma patients with resolved HBV infection following systemic chemotherapy.

Authors:  Haruhito Totani; Shigeru Kusumoto; Takashi Ishida; Arisa Masuda; Takashi Yoshida; Asahi Ito; Masaki Ri; Hirokazu Komatsu; Shuko Murakami; Masashi Mizokami; Ryuzo Ueda; Akio Niimi; Hiroshi Inagaki; Yasuhito Tanaka; Shinsuke Iida
Journal:  Int J Hematol       Date:  2015-01-30       Impact factor: 2.319

Review 6.  Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges.

Authors:  Maria Vela; Mariana Aris; Mercedes Llorente; Jose A Garcia-Sanz; Leonor Kremer
Journal:  Front Immunol       Date:  2015-01-30       Impact factor: 7.561

Review 7.  Hepatitis B Reactivation with Novel Agents in Non-Hodgkin's Lymphoma and Prevention Strategies.

Authors:  Oluwatobi O Ozoya; Lubomir Sokol; Samir Dalia
Journal:  J Clin Transl Hepatol       Date:  2016-06-15

Review 8.  Prevention of Hepatitis B reactivation in the setting of immunosuppression.

Authors:  Venessa Pattullo
Journal:  Clin Mol Hepatol       Date:  2016-06-13

9.  Furin-dependent CCL17-fused recombinant toxin controls HTLV-1 infection by targeting and eliminating infected CCR4-expressing cells in vitro and in vivo.

Authors:  Masateru Hiyoshi; Kazu Okuma; Seiji Tateyama; Kazuya Takizawa; Masumichi Saito; Madoka Kuramitsu; Kumiko Araki; Kazuhiro Morishita; Seiji Okada; Naoki Yamamoto; Arya Biragyn; Kazunari Yamaguchi; Isao Hamaguchi
Journal:  Retrovirology       Date:  2015-08-20       Impact factor: 4.602

10.  Fatal pneumonia and viremia due to human parainfluenza virus type 1 in a patient with adult T-cell leukemia-lymphoma treated with mogamulizumab.

Authors:  Keita Tamaki; Takeshi Kinjo; Hajime Aoyama; Takeaki Tomoyose; Sawako Nakachi; Taeko Hanashiro; Natsuki Shimabukuro; Iori Tedokon; Kazuho Morichika; Yukiko Nishi; Naoya Taira; Jiro Fujita; Naoki Yoshimi; Takuya Fukushima; Hiroaki Masuzaki
Journal:  J Infect Chemother       Date:  2015-07-10       Impact factor: 2.211
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.